FTRE

DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast c

Highlights: Designed to transform clinical trial operations for sponsors, sites and study teamsPersona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and qualityBuilds on Fortrea's flagship platform Xcellerate® to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations. By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversig

SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units ("RSUs") on March 10, 2026, to four newly hired employees. The award consisted of 130,000 RSUs that vest in three equal annual installments starting March 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an

144 - Fortrea Holdings Inc. (0001965040) (Subject)

144 - Fortrea Holdings Inc. (0001965040) (Subject)

TD Cowen upgraded Fortrea from Hold to Buy and set a new price target of $15.00

10-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea's chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea's portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea's early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea'

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

144 - Fortrea Holdings Inc. (0001965040) (Subject)